more accurate and prompt responses.
|REPORT||T&R Biofab, obtained license to commercialize (sale) "iPSC-based cardiomyocytes||DATE : 2020.09.11||VIEW : 495|
T&R Biofab, obtained license to commercialize (sale) "iPSC-based cardiomyocytes"
1st SEP. 2020.
T&R Biofab announced on the 1st SEP that it has signed a license agreement with iPS Academia Japan, Inc. to commercialize (sale) cardiomyocytes based on iPSC as a research tool for users’ internal research.
iPS Academia Japan has obtained sublicense rights on patents and patent applications of Kyoto University including the Center for iPS Cell Research Application (CiRA), a research center directed by Professor Shinya Yamanaka in Japan who won the Nobel Prize for developing iPSC in 2012. Based on the results of iPSC research by many institutions including Kyoto University in Japan, the company has a portfolio of patents related to iPSC, and based on this, it is actively carrying out technology licensing activities for iPSC research to institutes and companies around the world.
T&R BioFab has secured a number of iPSC lines that won IRB approval from Kyungpook National University Hospital in April, and is currently building a technology to produce cardiomyocytes from cell stocks that can be commercialized. Thus, T&R Biofab acquired the right to sell iPSC-derived cardiomyocytes as commercial products through commercialization licensing agreement with iPS Academia Japan.
Won-soo Yoon, CEO of T&R BioFab, said, "By 2021, we will produce 50 types of iPSC lines that have safety and stability that do not use virus and animal-derived pollutants, and we plan to expand our commercialized product line by developing various cell production technologies starting with this sales of cardiomyocytes."
In addition, T&R Biofab plans to expand its "business area using iPSC" through this contract, and will also use it to develop 3D bioprinting tissue and cell therapy products under way by R&D department. It is also expected to gain further momentum in developing products for regeneration of human tissues using stem cells under the "Act on the Safety and Support of Advanced Rehabilitation Medicine and Advanced Bio-medicine," which took effect last month.
|Prev ▲||There is no Next article.|
|Next ▼||T&R Biofab Announces Research Collaboration for the Development of a 3D Bio-printed Soft Tissue Scaffold||2020.02.06|